posted on 2021-03-05, 04:34authored byErica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres, Eddy S. Yang
Additional file 1: Supplementary Figure S1. Lapatinib concentration-time results from cycle 1 (triangles) and cycle 2 (circles). Vertical lines are standard error bars. Supplementary Figure S2. Plots of the Breast360 cancer signatures for each patient. PR are a) 002, b) 009; PD are c) 004, d) 005, e) 007, f) 008, g) 010, h) 013, i) 014, j) 022, k) 023. Inner circle: basal (red), her2-enhanced (pink), Lum B (lt. blue), Lum A (blue), TIS (green). Outer circle: tumor state (Claudin-low, differentiation), hormonal biology (AR, ER, ERBB2, ESR1, FOXA1, PGR), mutational susceptibility (BRCAness, HRD, p53 status), immune activity (CD8 + T cells, cytotoxicity), inhibition from tumor (TGFB, PDL1, IDO1, B7H3), inhibition from immune system (Treg, TIGIT, PDL2, Inflammation chemokines), tumor sensitivity (APM, apoptosis, proliferation), access to tumor (endothelial, stroma). Supplementary Table S1. Pharmacokinetic parameters for lapatinib during cycle 2 (steady-state). Abbreviations: AUC, area under the curve; Cmax, maximum concentration; CV, coefficient variation; Tmax time to maximum serum concentration; Elimination half-life, T1/2. Supplementary Table S2. Site of tissue biopsy and prior systemic treatments. Supplementary Table 3. Top Canonical Pathways.